STAAR Surgical Company (STAA) fair value analysis
Nasdaq · Updated 2026-10-19
STAA price how computed
Forward Fair Value verdict
UndervaluedSTAA is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $21.27
- Sector
- Healthcare
- 12-month range
- $16.10–$33.34
- Market cap
- $1.07B
- From 52-week high
- -36.2%
- Shares outstanding
- 50.1M
- Rank in Healthcare by discount to fair value
- #3 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
STAAR Surgical Company designs and manufactures implantable lenses and related surgical equipment used in ophthalmology procedures, particularly for vision correction. The company operates globally, serving customers in markets across North America, Europe, Asia, and other regions worldwide.
STAA currently ranks #3 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.07B
- P/E (trailing)
- 27x
- Revenue (TTM)
- $340M
- Net margin
- 1.1%
- EPS (TTM)
- $0.78
- Gross margin
- 74.5%
- Debt / equity
- 0.10
- Revenue growth (3-yr avg)
- 5.5%
- Shares outstanding
- 50.1M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 48 · neutral
- 50-day average
- $22.72
- 200-day average
- $23.56
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+260.0%)
2026-03 ▲ beat (+262.5%)
2025-12 ▼ miss (-94.8%)
2025-09 ▲ beat (+500.0%)
2025-06 ▲ beat (+76.8%)
2025-03 ▼ miss (-66.7%)
2024-12 ▼ miss (-2200.0%)
2024-09 ▲ beat (+11.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 7 hold · 1 sell (12 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $28
- Target vs last price
- +31.6%
What our data shows for STAA
- Our model validated 12 trailing price-to-earnings windows for STAA, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $16.10–$33.34.
- The 14-day relative strength index sits at a neutral 48.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for STAA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent STAA news
TickrTrends' derived news-sentiment signal for STAA is currently leaning positive, computed from recent coverage.
- STAAR Surgical Stock: A Recovery Story Priced As Growth (NASDAQ:STAA) (seekingalpha.com, 2026-10-02)
TickrTrends take: STAAR Surgical operates in the Healthcare sector and is currently assessed as Undervalued by TickrTrends, suggesting the market may not be fully reflecting its business fundamentals. The characterization of the company as a recovery story that is priced as growth indicates a potential disconnect between investor sentiment and the company's valuation metrics. For valuation-focused readers, monitoring whether the stock's pricing begins to align with its recovery trajectory and underlying worth will be important in determining if the current undervaluation thesis holds. - STAA Looks 38.4% Undervalued on GF Value™ Despite Profit Challenges (gurufocus.com, 2026-09-25)
TickrTrends take: STAA's assessment as undervalued by TickrTrends aligns with the GF Value analysis showing significant downside cushion, though investors should monitor whether the company can address the underlying profit challenges that may have created this valuation gap. The Healthcare sector positioning means operational improvements in profitability could be a key catalyst for narrowing the valuation discount. Readers focused on valuation metrics should track whether STAA's earnings trajectory moves toward justifying the current depressed price or whether the discount persists due to structural headwinds. - STAAR Surgical (STAA) Swings To Profit On China Rebound (insidermonkey.com, 2026-09-14)
TickrTrends take: STAAR Surgical's return to profitability amid China market recovery provides a concrete earnings development that supports TickrTrends' undervalued assessment for the Healthcare sector company. Valuation-focused readers should monitor whether this profitability swing translates into sustained margin expansion and whether China revenue growth maintains momentum, as these factors will be critical to justifying any price appreciation from current levels. The company's ability to convert geographic diversification into reliable earnings growth will determine if the undervalued designation proves prescient or requires recalibration.
What people are saying
Follow the STAA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — STAA's quality grade declined from A to C this week, indicating a notable deterioration in the company's fundamental metrics. The stock's sector discount rank improved to number 8 from number 17, suggesting it has become more attractively priced relative to other healthcare companies. Despite the weakened quality assessment, STAA remains classified as undervalued according to TickrTrends' current valuation verdict.
- 2026-10-05 — TickrTrends' derived indicators for STAA showed a decline in sector positioning this week. The stock's sector discount rank fell from #9 to #17, indicating a weaker valuation position relative to other healthcare sector companies. Despite this downward movement in the ranking, STAA maintains an undervalued verdict according to current valuation metrics.
- 2026-09-28 — STAA's technical indicators have shifted this week as the stock moved from a mixed trend state to a downtrend in its 50/200-day analysis, while the Relative Strength Index moved out of oversold territory into neutral range. The company's sector discount ranking improved to number 9 from number 15, indicating a stronger valuation position relative to other healthcare stocks. TickrTrends currently maintains an undervalued verdict for STAA.
- 2026-09-21 — TickrTrends' derived indicators for STAA showed a shift this week, with the RSI zone moving from neutral to oversold territory. The stock remains classified as undervalued according to current valuation metrics. This oversold reading suggests the stock may have experienced a notable decline during the week.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is STAA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), STAA is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is STAA's TickrTrends verdict?
STAA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does STAA compare to other Healthcare stocks?
STAA ranks #3 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is STAA overbought or oversold?
STAA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does STAA report earnings next?
STAA's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does STAA usually beat earnings estimates?
Over its last 8 reported quarters STAA beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about STAA?
Of 12 analysts covering STAA, 4 rate it a buy, 7 a hold and 1 a sell - hold-leaning, with a consensus price target of $28 (+31.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
STAA vs ADMA · STAA vs ALGN · STAA vs ANIP · STAA vs ASTH · STAA vs AZN